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THERE is increasing evidence recently to suggest that patients suffering from
Burkitt tumour produce factors of a specific immunological character directed
against antigens in the tumour. Burkitt et al. (1965) considered that there is
probable participation of immunological processes in the manifestation of certain
clinical observations made on patients suffering from the tumour. In particular,
the dramatic response of the tumour to unusually low doses of certain cytotoxic
drugs, failure of subsequent tumours to appear at sites of completely regressed
tumour, and the many cases ofauthentic long term remissions were believed to be
due, at least in part, to host defence mechanisms directed against the tumour.
The concept was further supported by the independent reports by Ngu (1966)
and Burkitt (1966) of almost complete, though transient, regression of jaw
tumours in two Burkitt tumour patients infused with plasma from cases in long
term remissions.
Suggestive laboratory evidence were also forthcoming. Using fluorescent
antibody tests, Klein etal. (1966) were able to demonstrate innumological reaction
between the cell surface of freshly isolated Burkitt tumour cells and serum glo-
bulins from a good number of Burkitt tumour patients as well as some adult
patients with other diseases, in East Africa. Osunkoya (1966) suggested that the
relative poor growth ofa Burkitt tumour cell line in cultures containing sera from
some Birkitttumourpatients as comparedwithserafrom healthyNigerian children
and adults may be due to anti-tumour humoral factors present in the serum of
these patients.
In the present study, two parameters-growth effect and membrane immuno-
fluorescence-were used in the comparison of the effects of serum from various
groups of individuals on a long established Burkitt tumour cell line. A third
parameter, that of detection of cytotoxic antibodies by the in vitro cytotoxic
test of Gorer and O'Gorman (1956) is the basis of a parallel study to be published
elsewhere.
MATERIALS AND METHODS
Birkcitt tumour cellB.-The target cells used in these series of experiments were
lymphoid cells (Strain OB3) established in continuous suspension culture from
ascitic fluid of a Nigerian boy aged 10 years suffering from abdominal Burkitt
tumour. The cells have been maintained in culture for about nine months at the
time they were tested. Cultures were maintained in medium TC 199 containing
25 to 30% pooled human serum obtained from Nigerian blood donors at U.C.H.,ANTI-BURKITT TUMOUR GLOBULINS
Ibadan, and supplemented with 0.4% chick embryo extract (Difco). Neomycin
(30 units/ml.) and mycostatin (50 units/ml.) were added to all cultures. The
cells grow readily in small aggregates with many single free floating cells present.
Viable Burkitt tumour cells harvested from stock cultures maintained in this
laboratory have been observed (unpublished) to regularly show a positive mem-
brane immunofluorescence when simply washed thrice in phosphate buffered
saline (PBS) pH 7-2, and stained with fluorescein-labelled anti-human globulin.
The membrane immunofluorescence is totally prevented if the harvested cells are
exposed to 0.25% trypsin in TC 199 for 30 minutes, at 370 C., before washing in
three changes of PBS, pH 7-2.
Test sera.-Single blood samples were obtained from the various groups of indi-
viduals listed in Tables I and II.
These comprise:
(a) 107 Nigerianblooddonors aged 18 to 50years presenting at the BloodBank,
U.C.H., Ibadan.
(b) 39 American Negro blood donors aged 25 to 51 years in New York, through
the kindness ofDrs. Burchenal and Oettgen.
(c) 44 American Caucasian blood donors aged 20 to 59 years in New York,
through the kindness ofDrs. Burchenal and Oettgen.
(d) 15 members of the American Peace Corps, aged 22 to 27 years, within a
week of their arrival in Nigeria, through the kindness of Dr. Friedland.
(e) 21 members of the American Peace Corps, aged 23 to 27 years who have
lived continuously in various parts of Nigeria for two or more years,
through the kindness of Dr. Friedland.
(f) 20 untreated Burkitt tumour patients aged 4 to 14 years, and one aged
20 years.
(g) 16 Burkitt tumour patients, symptom-free 3 months to 4 years after
complete withdrawal of cytotoxic therapy.
(h) 21 sick Nigerian children aged 3 to 12 years presenting with miscellaneous
acute diseases at the General Out Patient Department, U.C.H., Ibadan.
(i) 8 mothers and 6 fathers of Burkitt tumour patients; total 14.
(j) 14 untreated Nigerian patients with histological diagnosis of malignant
lymphoma. These include 5 Hodgkin's-type lymphoma, 3 reticulum cell
lymphoma, 3 lymphoblastic lymphoma, 1 stem cell lymphoma, 1 myeloma
and 1 case of chronic myeloid leukaemia presenting with generalised
superficial lymphadenopathy.
Serum was separated from the blood samples within 36 hours of collection.
Serum specimens were kept at 40 C. until use in this study, after which they were
deep frozen at -20° C. for further studies. Specimens were generally tested at
least one, but not more than four weeks after collection. Serum specimens.
from individuals inNew York were shipped by air to Ibadan at cabin temperature
Such specimens arrived in this laboratory within 36 hours ofdispatch.
Standard serum
This was a 90 ml. serum sample, separated from 200 ml. clotted blood collected
from a healthy adult Nigerian at one bleeding. Samples were kept frozen at
--20C. in 2 ml. aliquots.
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Tests
Serum samples were tested for their effects on Burkitt tumour cells using two
parameters, viz: (i) the effect on survival and growth of OB3 cells in vitro and (ii)
detection of anti-Burkitt (OB3) cell globulins in the test sera, by Moller's indirect
membrane immunofluorescence (" ring ") test on viable OB3 cells recovered from
cultures in (i). (Moller, 1961).
(i) Growth Experiments.-The layout of the experiments was as described in
a previous report (Osunkoya, 1966) on another Burkitt tumour cell line. A major
modification of the previous work was the rendering of cell harvested from stock
cultures free of any adsorbed or immunologically reactant surface globulin, by
trypsinisation and washing as described above.
Serum samples were tested in batches of twenty. 0-6 ml. of each serum was
measured into test tubes. 1*4 ml. TC 199 was then added to each tube to give a
2 ml. culture medium containing 30% test serum. 0-1 ml. supensions of washed
trypsinised cells calculated to give a viable cell population of 1-2 x 105 cells per
ml. culture was then added to each tube. Duplicate cultures containing the
standard serum were included in each batch of experiments. The cultures tubes
were tightly stoppered and incubated stationary at 370 C. Viable cell counts as
previously described (Osunkoya, 1965) were carried out on all cultures at 0-2
hours and again at 96-98 hours. Serum samples proved by nutrient broth culture
to be contaminated were excluded from growth experiments.
The growth effect ofeach test serum was expressed as a growth index, which is
the growth of OB3 cells in the test serum relative to growth in the standard serum.
This was calculated simply as the difference between the increase in viable cell
population in the test serum culture and the standard serum culture. Thus the
standard serum culture affords a comparison between the growth effect of indi-
vidual sera within the same and different batches of growth experiments. Test
sera in which there is less increase in numbers of viable cells per unit volume of
culture than in the standard serum, have a negative growth index; those in which
viable numbers are greater than in the standard serum have a positive growth
index.
(ii) Membrane immunoftuorescence tests.-After the final cell count (at 96-98
hours) in the growth experiments, each test culture was transferred into a small
(Kahn) test tube, and centrifuged at 250 g for 3 minutes. The cells were washed
twice bycentrifugation in PBS pH 7-2, and resuspended in 0 04 ml. PBS. 004 ml.
of a 1 in 5 dilution of fluorescein-labelled anti-human globulin (Burroughs and
Wellcome) was added and the tubes left standing at room temperature (250 C.)
with intermittent shaking, for 20 minutes. The cells were then washed in three
changes ofPBS pH 7-2 and resuspended in two drops of50% glycerine. One drop
of the cell suspension was then mounted on a glass slide, and the preparation
examined immediately under a Leitz fluorescence microscope using an Osram
HBO-200W mercury vapour light source.
The degree of fluorescence of each preparation was recorded as one of three
categories (0, +, or ++). Preparations in which no cells showed surface fluores-
cence were scored as 0. Those in which a distinct complete fluorescent ring out-
lined the cell surface in a good number ofcells (usually 10-50%) were scored as +.
Those showing bright surface fluorescence in the majority of cells (usually over
60%) were scored as ++. The later two categories were regarded as positive
tests. In some preparations fluorescent particles were present on the cell surface
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of many cells without forming the characteristic ring. These, as well as cells
showing intracellular fluorescence, a manifestation of non-viability, were ignored
in the assessment of category ofthe preparation.
RESULTTS
Growth Experiments
The growth index of serum samples from the different groups ofindividuals is
as shown in the scattergram (Fig. 1). There was wide variation in the growth
effect of the test sera on OB3 cells. The widest variation was in the Nigerian
blood donor group with growth indices ranging from -20 to +500. (Table I)
TABLE I.-Growth effect ofserafrom various individuals on OB3 cells.
Growth index*
Number ,
__ I_
Groups of individuals tested Range Median
Nigerian blood donors . . . . . 105 . -20 to +500 +120
Parents of Burkitt tumour patients . . 14 . -50 to +250 + 130
Burkitt tumour patients. Untreated . . 21 . -10 to +140 +60
Burkitt tumour patients. In remission. 16 . -120 to +250 +40
Sick Nigerian children with miscellaneous . 20 . -110 to +280 +90
Malignant lymphoma patients . . . 13 . + 10 to + 190 + 120
New York blood donors. Negroes . . 37 . -50 to +220 +70
New York blood donors. Caucasians . . 42 . -40 to + 190 +80
American Peace Corps volunteers. Newly . 15 . +60 to +430 +220
arrived in Nigeria
American Peace Corps volunteers. 2 yrs . 18 . -80 to +440 +130
resident in Nigeria
* Growth index = (increase in viable cell population in Test serum culture)
minus
(increase in viable cell population in Standard serum culture).
with a median value of +120. There was no significant difference between the
effects of sera from Negro and Caucasian New York citizens, median values
being +70 and +80 respectively. Both groups however, lack individuals with
unusually high growth promoting effect present in the adult Nigerian group.
The effect, if any, of shipping on the growth effect of sera from New York is yet
to be determined.
The Peace Corps groups show a distribution not unlike those ofNigerian blood
donors, the long resident members of the corps tending to manifest lower growth
indices. The numbers tested in the Peace Corps sub-groups were unfortunately
too small to allow definite conclusions to be drawn from the apparent difference
between thenewly arrived (median, +220) andthe longresidentmembers (median,
+130) of the American Peace Corps in Nigeria.
As a group, the sera from Burkitt tumour patients showed the lowest growth
promoting effects. The growth index range was -110 to +250. In this group
sera from patients in remission showed lower growth promoting effects (median
+40) than in the untreated tumour-bearing patients (median +60). The three
patients with the lowest growth indices had been symptom-free 2 or more years
after treatment.
The distribution of growth indices of sera from parents of Burkitt tumour
patients, patients with malignant lymphoma other than Burkitt tumour, and
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other sick children of the same age group as Burkitt tumour patients were essen-
tially within the range of those of healthy Nigerian blood donors. The two sick
children with sera with unusually low growth indices (Fig. 1) both had " fever and
anaemia of unknown cause ".
Membrane immunofluorescence tests on viable cultured cells
OB3 cells are capable of showing a positive membrane immunofluorescence
reaction when challenged with suitable human test sera (Table II). Using the
criteria listed above for scoring ofa positive test, sera from 41% ofNigerian blood
donors showed a positive reaction. 22% and 18% of New York blood donors of
Negro and Caucasian ethnic groups respectively, gave a positive reaction.
TABLE II.-Membrane immunofluorescence reaction on OB3 cells cultured in sera
from various individuals
Age Number Number of %
Groups of individuals (yrs). tested positive sera Positive sera
Nigerian blood donors . . . 18-50 . 107 . 44 . 41
Parents of Burkitt tumour patients . . Not known . 14 . 9 . 64
Burkitt tumour patients . . . . 4-20 37 . 21 . 57
Sick Nigerian children with miscellaneous . 3-12 . 21 . 4 . 19
complaints
Malignant lymphoma patients. (Nigerians) 20-50 . 14 . 6 . 43
New York blood donors. Negroes . 25-51 . 39 . 9 . 22
New York blood donors. Caucasians. 20-59 . 44 . 8 . 18
American Peace Corps volunteers. Newly . 22-27 . 15 . 1 . 7
arrived in Nigeria
American Peace Corps volunteers. 2 years 23-27 21 . 7 . 33
resident in Nigeria.
Only one out of 15 (7%) newly arrived American Peace Corps volunteers
produced a positive serum. Seven out of 21 (33%) of the volunteers that have
been living in Nigeria for two or more years were positive.
Sera from parents of Burkitt tumour patients showed the highest proportion
of positive samples (64%), followed closely by the Burkitt tumour patient group
(57%).
Sera from adult patients with various types of malignant lymphomas showed
a positive rate (43%) closely similar to that of healthy Nigerian blood donors.
Lastly, only 4 out of 21 (19%) of sick children with miscellaneous complaints
produced positive sera.
There was no correlation between the growth effect or outcome of the fluores-
cent antibody tests of sera from the Nigerian donors and their respective ABO
and Rh blood groups. There was also no correlation between the growth effect of
individual serum samples and their respective membrane immunofluorescence
reaction on OB3 cells. Thus, a serum sample with a low growth index did not
necessarily give a positive membrane immunofluorescence reaction.
DISCUSSION
The knowledge gained in the growth experiments is closely similar to that
reported in an earlier study in which another Burkitt tumour cell line (Strain
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OB1) and a different series of sera from adult Nigerians and Burkitt tumour
patients were tested, (Osunkoya, 1966).
It is likely, as has already been suggested, that several factors particularly of a
nutritional nature are involved, in addition to probable immunological processes,
in the manifestation of the effect of a serum sample on the growth of Burkitt
tumour cells in vitro. The active participation of immune or related processes is
however suggested by the trend observed by Ngu et al. (1966) between the lgM
level of some serum samples and their growth effects on a Burkitt tumour cell
line (OB6).
It is well known in tissue culture work that some human and animal sera
contain thermolabile substances of as yet unknown nature, which make such sera
" toxic " to cell growth in vitro. An immunological phenomenon is still to be
excluded in the search for a satisfactory explanation to account for the action of
these " toxic " sera. Sera heated at 560 C. for 30 minutes regularly have a lower
growth index than the respective uninactivated serum when tested on Burkitt
tumour cell lines, (unpublished).
The result of the immunofluorescence tests on OB3 cells cultured in sera from
various individuals are of interest, and essentially confirms the results of Klein
et al. (1966) concerning East Africans. Sera from Swedish blood donors tested by
these workers were however negative.
Several conclusions are readily drawn from the set offigures shown in Table II.
We can now say that (i) cells that have been propagated in tissue culture for more
than nine months after isolation from a patient suffering from Burkitt tumour
bear on their surface moieties perhaps of an antigenic character, which react with
human serum globulins to such a degree as to be detectable by the indirect (sand-
wich) fluorescent antibody reaction. (ii) Some Nigerians as well as North
Americans do possess serum globulins which have affinity for the surface of these
cells. (iii) Blood donors in New York have a lower incidence of individuals
possessing such globulins as compared with Nigerian blood donors (X2 = 9-134.
p < 0.005). (iv) Burkitt tumour patients show more tendency of having this
type of globulin than sick Nigerian children of comparable age (X2 = 6-306.
p < 0.025). (v) Apparently a higher proportion ofAmericans 2 years resident in
Nigeria produce this serum globulin, than a comparable newly arrived group
(p = 0.064). (vi) The New York American Caucasian is as likely to possess this
globulin as the New York Negro.
The interpretation of these findings can, at this stage of our studies, be only a
matter of conjecture. If the positive " ring " test (Moller, 1961) is a genuine
index ofan immunological reaction, then it would appear that antibodies to surface
antigens on OB3 cells are present in detectable concentration in a little less than
half ofNigerian blood donors, and about a fifth of New York blood donors. The
incidence of positive individuals is quite low in Nigerian children unless they are
suffering or have suffered from Burkitt tumour.
The nature of the reactant antigens on the surface of Burkitt tumour cells is
not known. The probability that the antigens are Burkitt tumour specific has
much to commend itself, but several other possibilities have to be considered for
exclusion, particularly if cell lines are used in the search for experimental proof of
this surmise.
The non-correlation of positive sera with ABO and rhesus blood group of
donors has been mentioned already. The combined incidence ofAnti-M, N and S
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haemagglutinins in the sera of Nigerian blood donors is less than 10% (Luzzatto
personal communication), a figure too low to account for an incidence ofover 40%
positive sera in the Nigerian blood donors studied. Klein et al. (1966) were also
able to exclude the involvement of blood group antigens in the analysis of their
results.
The increasing reports of contamination of cell cultures by pleuropneumonia-
like organisms (PPLO), with their characteristic tendency to aggregate on cell
surfaces, brings this class of organisms under consideration in any immunological
tests involving the cell surface ofcultured cells (Edwards and Fogh, 1960; Kraemer
et al., 1963; Fogh and Fogh, 1964; Holmgren find Payne, 1966). Electron micro-
scopic examination have so far failed to demonstrate Mycoplasma (PPLO) in
OB3 cultures (Dalton, personal communication).
The attractive hypothesis of virus-induced, insect-vectored aetiology of
Burkitt tumour (Davies, quoted by Burkitt, 1962a; Burkitt, 1962b; Stanley,
1966) has given much impetus to the search for viral agents in Burkitt tumour
materials. Herpes-type virus particles have been demonstrated in several
Burkitt tumour cell lines (Epstein et al., 1964, 1965; Stewart et al., 1965; Rabson
et al., 1966). The point in time at which the cells were infected by this viral
agent, as well as its importance if any, in the aetiogenesis of Burkitt tumour are
still subjectsofcontroversy.* [No virusparticleswere seenin OB3 cells byelectron
microscopy, at the time they were used in the present study (Dalton, personal
communication).] The role of several other groups of viruses which have been
isolated from Burkitt tumour materials is not clear. Herpes simplex virus has
been isolated directly from tumour biopsy material in afew out ofseveral attempts
(Woodall et al., 1965; Simons and Ross, 1965. Dalldorf and Bergmaini (1964)
isolated filterable antigenically-related agents now known to be mycoplasma from
tumour, bone marrow and faeces ofsix out ofeight East African children suffering
from Burkitt tumour. Lastly, reovirus type 3, a virus whose exact role, if any,
in the pathogenesis of murine lymphoma is as yet not clear, (Stanley, 1966;
Stanley et al., 1966(b)) have also been isolated from Burkitt tumour biopsy
materials, including ascitic fluid (Bell et al., 1966; Bell, 1966).
There is striking similarity between the results of the present investigations
and reports on some serological investigations carried out in East Africa in which
it was shown that 53 out of 72 (73%) Burkitt tumour patients had demonstrable
antibodies to reovirus type 3 as compared with 12 out of 65 (18%) healthy East
African children, a highly significant difference, (Bell, 1966).
While awaiting the characterisation of the cell surface antigens on OB3 and
other Burkitt tumour cells, the results of the present study would suggest that
some of these antigens may be related to the pathogenesis of Burkitt tumour,
since it is children with this tumour as well as their relatives that produced the
highest incidence of positive sera. This conclusion supports the concept of
Burkitt tumour being a rare aberrant response to an infective, probably viral
agent which occurs commonly in tropical Africa. (Haddow and McCallum, 1962;
Burkitt, 1963). It is possible that this agent or a closely related variant also
occurs in and around New York. It is considered that ease of perpetuation and
transmission, and more frequent exposure to the agent may account for the rela-
tively higher incidence of Burkitt's tumour in Africa.
* Two months after this paper was submitted for publication, occasional herpes-like virus particles
were seen in a few OB3 cells by electron microscopy. (V. H. Zeve, 1966, personal communication).
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SUMMARY
(1) Sera from various individuals were tested on cells from a Burkitt tumour
cell line (OB3), for effect on growth of these cells in vitro, and for presence of
antibodies to surface antigens on these cells.
(2) Sera from Burkitt tumour patients, particularly those in long-term remis-
sion, have relatively low growth promoting effects on OB3 cells.
(3) Using the indirect immunofluorescence reaction, antibodies to surface
antigens on living OB3 cells were detected in serum samples from a little less than
half ofNigerian blood donors, as compared with a fifth ofNew York blood donors
tested (p < 0.005). There was no significant difference in the incidence ofpositive
sera between Negro and Caucasian New York blood donors. The incidence of
positive sera was quite low in sick Nigerian children unless they are suffering or
have suffered from Burkitt tumour (p < 0.025). Although a higher proportion
of young Americans resident in Nigeria produced positive sera than a comparable
newly arrived group, and although it would appear that the incidence of positive
sera was highest in the parents of Burkitt tumour patients the small numbers
tested in these groups preclude statistical significance.
(4) The nature of the surface antigens on Burkitt tumour cells is discussed in
the light of the above findings. It is considered that these antigens are related
to the aetiogenesis of Burkitt tumour, and may be infective in origin.
(5) There was no correlation between the growth effect of serum samples and
their respective membrane immunofluorescence results.
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